ABT
Abbott Laboratories
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-17/100
Last price
98.39
▼ 1.71 (1.70%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
100.20
Prev close
100.10
Day high
100.95
Day low
97.94
Volume
10.58M
Market cap
$169.85B
P/E (TTM)
32.29
52W range
81.97 – 135.13
Day trading desk
Gap from prior close
+0.10%
Prior close 100.10
VWAP
98.79
-0.40% from price
Relative volume
1.10×
Normal
Session range
3.07%
97.94 – 100.95
Position in range
15%
Near session low
ATR (14D)
2.22
2.25% of price
Prior day high
100.70
PDH
Prior day low
97.39
PDL
Bid / ask spread
—
Quote not published
Session volume
10.56M
Avg 9.57M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.76%
-4.7%
1M
-9.39%
-10.5%
3M
+3.13%
-1.4%
6M
-3.60%
-21.8%
YTD
-21.65%
-35.9%
1Y
-27.07%
-43.5%
3Y
+1.35%
-80.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ABT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+35.76K
Net buying
Buy transactions
16
440.46K shares
Sell transactions
3
404.71K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
8.51M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | MCCOY JOHN A. JR Officer |
SELL | 27 | $2.96K | Direct |
| Aug 25, 26 | FORD ROBERT B. Chief Executive Officer |
CONVERSION | 398.83K | $21.55M | Direct |
| Aug 25, 26 | FORD ROBERT B. Chief Executive Officer |
SELL | 398.83K | $46.20M | Direct |
| Aug 11, 26 | MORRONE LOUIS H Officer |
SELL | 5.85K | $642.51K | Direct |
| May 7, 26 | STRATTON JOHN G. Director |
BUY | 2.00K | $173.64K | Direct |
| Apr 27, 26 | STARKS DANIEL J Director |
BUY | 10.00K | $926.54K | Direct |
| Apr 24, 26 | KUMBIER MICHELLE A Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | BABINEAUX CLAIRE FONTENOT Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | O GRADY MICHAEL G Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | BLOUNT SALLY E Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | ROMAN MICHAEL F Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | GONZALEZ PATRICIA PAOLA Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | AHUJA NITA M.D. Director |
STOCK | 2.29K | $0 | Direct |
| Apr 24, 26 | MCDEW DARREN W Director |
STOCK | 2.29K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLEN HUBERT L. |
Officer | 200.28K | Stock Award(Grant) |
BOUDREAU PHILIP P |
Chief Financial Officer | — | Purchase |
CONROY KEVIN T |
Director | 133.74K | Stock Award(Grant) |
EARNHARDT LISA D |
Officer | 98.98K | Stock Award(Grant) |
FORD ROBERT B. |
Chief Executive Officer | 522.66K | Conversion of Exercise of derivative security |
MORELAND MARY K |
Officer | 116.14K | Sale |
SALVADORI DANIEL GESUA SIVE |
Officer | 146.38K | Sale |
SCOGGINS CHRISTOPHER J |
Officer | 82.12K | Stock Award(Grant) |
STARKS DANIEL J |
Director | 6.75M | Purchase |
WAINER ANDREA F |
Officer | 74.38K | Sale |
Fundamentals
Market cap$169.85B
Enterprise value$197.62B
Revenue (TTM)$46.58B
Gross profit$26.48B
EBITDA$11.68B
Net income$5.40B
EPS (TTM)$3.04
Free cash flow$7.21B
Total cash$5.60B
Total debt$32.72B
Book value / share$29.54
Shares outstanding1.73B
Float1.72B
Short % of float1.29%
Dividend yield2.52%
Beta (5Y)0.58
Valuation & profitability ratios
Trailing P/E32.29
Forward P/E16.18
PEG ratio1.84
Price / sales—
Price / book3.32
EV / revenue4.24
EV / EBITDA16.92
Gross margin56.85%
Operating margin14.71%
Profit margin11.65%
Return on equity10.58%
Return on assets5.33%
Debt / equity63.21
Current ratio1.38
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $44.33B | $41.95B | $40.11B | $43.65B | +5.7% |
| Operating revenue | $44.33B | $41.95B | $40.11B | $43.65B | +5.7% |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | +3.3% |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | +7.6% |
| Research & development | $2.94B | $2.84B | $2.74B | $2.89B | +3.4% |
| Selling, general & admin | $12.33B | $11.70B | $10.95B | $11.25B | +5.4% |
| Total operating expense | $16.96B | $16.42B | $15.66B | $16.15B | +3.3% |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | +18.0% |
| Net interest income | -$185.00M | -$215.00M | -$252.00M | -$375.00M | +14.0% |
| Pre-tax income | $8.47B | $7.01B | $6.66B | $8.31B | +20.7% |
| Tax provision | $1.94B | -$6.39B | $941.00M | $1.37B | +130.4% |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | -51.3% |
| Net income to common | $6.52B | $13.40B | $5.72B | $6.93B | -51.3% |
| Basic EPS | 3.76 | 7.74 | 3.30 | 3.99 | -51.5% |
| Diluted EPS | 3.72 | 7.64 | 3.26 | 3.91 | -51.3% |
| EBIT | $8.96B | $7.57B | $7.30B | $8.86B | +18.3% |
| EBITDA | $12.07B | $10.79B | $10.54B | $12.13B | +11.9% |
| Basic shares | 1.74B | 1.73B | 1.73B | 1.74B | +0.3% |
| Diluted shares | 1.75B | 1.75B | 1.75B | 1.76B | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.52B | $7.62B | $6.90B | $9.88B | +11.9% |
| Cash & short-term investments | $8.94B | $7.97B | $7.28B | $10.17B | +12.2% |
| Accounts receivable | $7.93B | $6.92B | $6.57B | $6.22B | +14.5% |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | +4.7% |
| Total current assets | $26.00B | $23.66B | $22.67B | $25.22B | +9.9% |
| Property, plant & equipment | $11.82B | $10.66B | $10.15B | $9.16B | +10.9% |
| Goodwill & intangibles | $29.56B | $29.75B | $32.49B | $33.25B | -0.7% |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | +6.5% |
| Total current liabilities | $16.50B | $14.16B | $13.84B | $15.49B | +16.5% |
| Current debt | $3.03B | $1.50B | $1.08B | $2.25B | +102.2% |
| Long-term debt | $9.90B | $12.63B | $13.60B | $14.52B | -21.6% |
| Total debt | $13.86B | $15.02B | $15.63B | $17.72B | -7.7% |
| Total liabilities | $33.94B | $33.51B | $34.39B | $37.53B | +1.3% |
| Retained earnings | $49.78B | $47.26B | $37.55B | $35.26B | +5.3% |
| Shareholder equity | $52.13B | $47.66B | $38.60B | $36.69B | +9.4% |
| Working capital | $9.50B | $9.50B | $8.83B | $9.73B | +0.0% |
| Net tangible assets | $22.57B | $17.91B | $6.11B | $3.43B | +26.0% |
| Shares issued | 2.00B | 1.99B | 1.99B | 1.99B | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | -51.3% |
| Depreciation & amortisation | $3.12B | $3.22B | $3.24B | $3.27B | -3.2% |
| Stock-based compensation | $664.00M | $673.00M | $644.00M | $685.00M | -1.3% |
| Change in working capital | -$803.00M | -$9.22B | -$2.48B | -$1.52B | +91.3% |
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | +11.8% |
| Capital expenditure | -$2.17B | -$2.21B | -$2.20B | -$1.78B | +1.6% |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -3.6% |
| Share buybacks | -$893.00M | -$1.29B | -$1.23B | -$3.79B | +31.0% |
| Dividends paid | -$4.12B | -$3.84B | -$3.56B | -$3.31B | -7.3% |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -16.7% |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | +16.4% |
| End cash position | $8.52B | $7.62B | $6.90B | $9.88B | +11.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | — | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | — |
| Operating revenue | — | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | — |
| Cost of revenue | — | $4.89B | $4.92B | $5.08B | $4.85B | $4.47B | — |
| Gross profit | — | $6.27B | $6.54B | $6.29B | $6.29B | $5.89B | — |
| Research & development | — | $767.00M | $735.00M | $766.00M | $725.00M | $716.00M | — |
| Selling, general & admin | — | $3.74B | $3.13B | $3.05B | $3.09B | $3.06B | — |
| Total operating expense | — | $4.93B | $4.29B | $4.24B | $4.24B | $4.20B | — |
| Operating income | — | $1.34B | $2.25B | $2.06B | $2.05B | $1.69B | — |
| Net interest income | — | -$68.00M | -$42.00M | -$44.00M | -$50.00M | -$49.00M | — |
| Pre-tax income | — | $1.45B | $2.36B | $2.18B | $2.15B | $1.78B | — |
| Tax provision | — | $372.00M | $582.00M | $536.00M | $371.00M | $453.00M | — |
| Net income | — | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | — |
| Net income to common | — | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | — |
| Basic EPS | 0.53 | 0.62 | 1.02 | 0.95 | 1.02 | — | -14.5% |
| Diluted EPS | 0.53 | 0.61 | 1.01 | 0.94 | 1.01 | — | -13.1% |
| EBIT | — | $1.62B | $2.48B | $2.30B | $2.27B | $1.91B | — |
| EBITDA | — | $2.43B | $3.27B | $3.09B | $3.05B | $2.67B | — |
| Basic shares | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | — | -0.1% |
| Diluted shares | 1.74B | 1.75B | 1.75B | 1.75B | 1.75B | — | -0.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B | -20.2% |
| Cash & short-term investments | $7.29B | $8.94B | $7.73B | $7.28B | $6.84B | -18.4% |
| Accounts receivable | $8.21B | $7.93B | $8.14B | $7.97B | $7.33B | +3.5% |
| Inventory | $6.99B | $6.49B | $6.71B | $6.95B | $6.64B | +7.7% |
| Total current assets | $25.51B | $26.00B | $24.84B | $24.47B | $23.15B | -1.9% |
| Property, plant & equipment | $12.38B | $11.82B | $11.50B | $11.39B | $10.93B | +4.7% |
| Goodwill & intangibles | $53.10B | $29.56B | $29.57B | $29.87B | $29.62B | +79.6% |
| Total assets | $110.43B | $86.71B | $84.18B | $84.00B | $81.45B | +27.3% |
| Total current liabilities | $18.38B | $16.50B | $14.58B | $13.44B | $13.00B | +11.4% |
| Current debt | $4.41B | $3.03B | $1.34B | $507.00M | $506.00M | +45.4% |
| Long-term debt | $29.64B | $9.90B | $11.60B | $12.93B | $12.74B | +199.5% |
| Total debt | $34.05B | $13.86B | $12.94B | $13.44B | $13.24B | +145.6% |
| Total liabilities | $57.73B | $33.94B | $32.92B | $33.17B | $32.38B | +70.1% |
| Retained earnings | $49.96B | $49.78B | $49.10B | $48.47B | $47.72B | +0.4% |
| Shareholder equity | $52.06B | $52.13B | $50.95B | $50.56B | $48.81B | -0.1% |
| Working capital | $7.13B | $9.50B | $10.26B | $11.03B | $10.15B | -24.9% |
| Net tangible assets | -$1.03B | $22.57B | $21.39B | $20.69B | $19.19B | -104.6% |
| Shares issued | 2.00B | 2.00B | 2.00B | 2.00B | 2.00B | +0.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | -39.4% |
| Depreciation & amortisation | $803.00M | $792.00M | $791.00M | $777.00M | $756.00M | +1.4% |
| Stock-based compensation | $317.00M | $113.00M | $120.00M | $142.00M | $289.00M | +180.5% |
| Change in working capital | -$462.00M | $110.00M | $11.00M | -$407.00M | -$517.00M | -520.0% |
| Operating cash flow | $1.31B | $3.31B | $2.79B | $2.05B | $1.42B | -60.3% |
| Capital expenditure | -$399.00M | -$689.00M | -$496.00M | -$502.00M | -$484.00M | +42.1% |
| Investing cash flow | -$20.32B | -$913.00M | -$457.00M | -$582.00M | -$470.00M | -2,126.1% |
| Share buybacks | -$180.00M | -$302.00M | -$305.00M | -$6.00M | -$280.00M | +40.4% |
| Dividends paid | -$1.10B | -$1.03B | -$1.03B | -$1.03B | -$1.03B | -6.6% |
| Financing cash flow | $17.31B | -$1.40B | -$1.76B | -$1.10B | -$2.06B | +1,339.3% |
| Free cash flow | $916.00M | $2.63B | $2.29B | $1.54B | $933.00M | -65.1% |
| End cash position | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B | -20.2% |
Options analytics
Put / call volume
0.92
Call-heavy session
Put / call open interest
1.39
Positioning, not flow
Max pain
101.00
+2.9% from spot
ATM implied vol
37.2%
Nearest strike to spot
Skew (10% OTM)
-3.5%
Calls bid over puts
Call volume
333
Contracts, this expiry
Put volume
306
Contracts, this expiry
Heaviest call OI
101.00
333 contracts
Heaviest put OI
95.00
849 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.28 | 1.31 | +2.6% |
| Mar 2026 | 1.15 | 1.15 | +0.3% |
| Dec 2025 | 1.49 | 1.50 | +0.3% |
| Sep 2025 | 1.30 | 1.30 | +0.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.41 | 22 | $12.99B | +14.3% |
| Next quarter | 1.64 | 21 | $13.54B | +18.2% |
| Current year | 5.52 | 26 | $50.20B | +13.3% |
| Next year | 6.07 | 26 | $54.53B | +8.6% |
Analyst targets & ownership
Mean target$120.74
High target$135.00
Low target$103.00
Implied upside22.71%
Analyst count25
ConsensusSTRONG BUY
Strong buy / Buy4 / 19
Hold4
Sell / Strong sell0 / 0
Held by insiders0.49%
Held by institutions81.79%
Institutions holding3.78K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
99.91
-1.51% from price
SMA 20
101.43
-3.22% from price
SMA 50
106.65
-7.96% from price
SMA 100
99.17
-0.79% from price
SMA 200
103.74
-5.38% from price
EMA 12
100.19
-1.80% from price
EMA 26
102.46
-3.97% from price
EMA 50
103.13
-4.60% from price
RSI (14)
36.2
Neutral
MACD (12,26,9)
-2.27
Hist -0.28
ATR (14)
2.22
2.26% of price
Realised vol 30D
20.6%
Annualised
Bollinger upper
105.76
20, 2σ
Bollinger lower
97.10
20, 2σ
50 / 200 cross
Golden
106.65 vs 103.74
Trend bias
Below 200
-5.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.04
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
20.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-38.5%
Peak to trough
Max drawdown 5Y
-41.6%
Peak to trough
ATR 14
2.22
2.26% of price
Beta (reported)
0.58
5Y monthly, from filing
Short interest
Shares short
19.91M
Prior 20.38M
Change vs prior
-2.3%
Shorts covering
% of float
1.29%
Normal
% of shares out
1.15%
Against total outstanding
Days to cover
2.5
Liquid
Float
1.72B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Rothschild & Co | UPGRADE | Neutral | Buy |
| Sep 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 25, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 21, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 14, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Jul 28, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 17, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$2.52 / yr
Forward yield2.52%
5-year avg yield1.84%
Payout ratio78.71%
Ex-dividend dateOct 15, 2026
Next pay dateNov 16, 2026
Last split10000:4798
Split dateJan 2, 2013
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-20
Periodic Financial Reports
10-Q · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-16
Annual report of employee stock purchase
11-K · 2026-06-18
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-27
Periodic Financial Reports
10-Q · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-27
Offering Registrations
S-8 · 2026-04-24
Headlines
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
Zacks · 5h ago
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield
24/7 Wall St. · 10h ago
Amex GBT Announces Planned CEO Transition
Business Wire · 11h ago
These 5 Dividend Kings Raised Their Payouts The Most Over The Last Year
24/7 Wall St. · 13h ago
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News
24/7 Wall St. · 14h ago
If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock?
Trefis · 14h ago
Disposable Medical Device Market to Reach USD 144.85 Billion by 2030, Growing at a CAGR of 4.9% – MarketsandMarkets™
GlobeNewswire · 1d ago
Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor
MT Newswires · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.